Articles related to OBESITY/WEIGHT MANAGEMENT

Six weeks of moderate sleep restriction increased weight, waist circumference, and sedentary time in adults with baseline adequate sleep and elevated cardiometabolic risk.

The FDA has begun reviewing generic tirzepatide applications as global competition accelerates, despite US patent protections limiting near-term availability.

A 4-week randomized trial in 20 obese men with hypercholesterolemia found that intermittent hypoxic training combined with caloric restriction produced greater reductions in LDL-C, total cholesterol, and triglycerides compared with normoxic training under identical dietary conditions.

The American College of Physicians issued a living clinical guideline recommending semaglutide and tirzepatide as first-line pharmacologic treatments with lifestyle modifications for nonpregnant adults with obesity (BMI 30 kg/m2 or higher) or overweight (BMI 27 to 30 kg/m2) with at least one weight-related comorbidity, with phentermine-topiramate, liraglutide, and naltrexone-bupropion designated as second-, third-, and fourth-line options respectively based on GRADE evidence review.

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

Several recent studies link daily avocado consumption to lower dietary glycemic load, reduced diabetes risk in women, and modest blood pressure improvements in prediabetes patients, though small sample sizes and short follow-up periods limit the conclusions.